Targeting class I histone deacetylases in cancer therapy

Abstract excerpt

INTRODUCTION: Class I histone deacetylases (HDACs) are often overexpressed in cancer, and their inhibition typically leads cancer cells, but not normal cells, to apoptosis. Hence, the field of cancer therapy has experienced a continued surge in the development of HDAC inhibitors. AREAS COVERED: Class I comprises of HDAC1, 2, 3 and 8. HDAC1, 2 and 3 are active as subunits of multiprotein complexes while an HDAC8...

Topics

Join the communities discussing this publication.

• Acute Myeloid Leukemia Research
• Epigenetics and DNA Methylation
• Histone Deacetylase Inhibitors Research